pembrolizumab Deficient DNA Mismatch Repair (dMMR), +5 more biomarkers Endometrial Carcinoma Advanced, +1 more state Subsequent line pembrolizumab immunotherapy
dostarlimab Deficient DNA Mismatch Repair (dMMR), +5 more biomarkers Malignant Solid Tumor Advanced, +1 more state No standard/acceptable treatment, +1 more context dostarlimab immunotherapy
dostarlimab Deficient DNA Mismatch Repair (dMMR), +5 more biomarkers Endometrial Carcinoma Advanced, +1 more state Subsequent line dostarlimab immunotherapy
pembrolizumab Deficient DNA Mismatch Repair (dMMR), +5 more biomarkers Colorectal Carcinoma Metastatic, +1 more state pembrolizumab immunotherapy
pembrolizumab Deficient DNA Mismatch Repair (dMMR), +5 more biomarkers Malignant Solid Tumor Metastatic, +1 more state No standard/acceptable treatment, +1 more context pembrolizumab immunotherapy
ipilimumab + nivolumab Deficient DNA Mismatch Repair (dMMR), +5 more biomarkers Colorectal Carcinoma Metastatic Subsequent line ipilimumab, +1 more drug immunotherapy
nivolumab Deficient DNA Mismatch Repair (dMMR), +5 more biomarkers Colorectal Carcinoma Metastatic Subsequent line nivolumab immunotherapy
avelumab Deficient DNA Mismatch Repair (dMMR), +5 more biomarkers Endometrial Carcinoma Metastatic, +1 more state Subsequent line avelumab immunotherapy
dostarlimab Deficient DNA Mismatch Repair (dMMR), +5 more biomarkers Small Intestinal Adenocarcinoma Advanced, +1 more state First line, +1 more context dostarlimab immunotherapy
dostarlimab Deficient DNA Mismatch Repair (dMMR), +5 more biomarkers Biliary Tract Carcinoma, +1 more condition Advanced, +1 more state No standard/acceptable treatment, +1 more context dostarlimab immunotherapy
dostarlimab Deficient DNA Mismatch Repair (dMMR), +5 more biomarkers Endometrial Carcinoma Advanced, +1 more state Subsequent line dostarlimab immunotherapy
dostarlimab Deficient DNA Mismatch Repair (dMMR), +5 more biomarkers Fallopian Tube Carcinoma, +2 more conditions Advanced, +1 more state dostarlimab immunotherapy